Atlas Trials

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Clinical trial NCT01514344 · COMPLETED

Trial details

NCT number
NCT01514344
Sponsor
Andres J. M. Ferreri
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Start date
2011-12-01
Primary completion
2014-10-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.